Basic Research

 

The faculty at CVINJ has participated in the development and evaluation of over one hundred cardiovascular agents and devices, including beta blockers for heart failure, diuretics, ACE inhibitors for heart failure and coronary heart disease, HMG CoA reductase inhibitors for high-risk patients, nitrates, angiotensin-II receptor antagonists, anti-arrhythmic agents, dual ACE-endopeptidase inhibitors, and endothelin antagonists, among others. The use of statins and ACE inhibitors has resulted in a 30% decrease in mortality in patients with cardiovascular disease.